Vetoquinol (VETO) Q3 2024 TU earnings summary

Executive summary

• Nine-month sales reached €398 million, up 1.8% at constant exchange rates and 1.6% on a reported basis compared to the same period last year.

• Essential products contributed €241 million, growing 3.9% and representing 61% of total sales, up from 59% a year ago.

Financial highlights

• Q3 2024 sales were €134 million, stable at -0.5% at constant exchange rates compared to Q3 2023.

• Negative currency impacts totaled €-1 million, mainly from the Americas and Asia Pacific/Rest of World, partially offset by a €1.4 million positive impact in Europe.

• Cash position improved during Q3 2024.

Outlook and guidance

• Next financial update scheduled for January 30, 2025, with annual sales results.